Aduro's pancreatic cancer drug fails in mid-stage study

Stephen NewmanLast Update : Monday 16 May 2016 - 4:17 PM
Aduro's pancreatic cancer drug fails in mid-stage study

<span class="articleLocation”>Aduro Biotech Inc said its pancreatic cancer drug did not improve overall survival in patients who did not show improvement after at least two prior therapies, in a mid-stage study.

In the study, patients were given either CRS-207 or chemotherapy or a combination of CRS-207 with Aduro’s GVAX Pancreas, the company said on Monday.

Aduro’s shares fell 33 percent to $7.14 in premarket trading.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Kirti Pandey)

Source: Reuters Health

Short Link
2016-05-16 2016-05-16
Leave a Reply
Required fields*

Your email address will not be published.

Comments Rules :

عدم الإساءة للكاتب أو للأشخاص أو للمقدسات أو مهاجمة الأديان أو الذات الالهية. والابتعاد عن التحريض الطائفي والعنصري والشتائم.

Type a small note about the comments posted on your site (you can hide this note from comments settings)

Stephen Newman